Aveed
Biological
Endo Pharmaceuticals Inc.
Total Payments
$433,106
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $433,106 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $433,106 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury | Endo Pharmaceuticals Inc. | $226,437 | 0 |
| Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer | Endo Pharmaceuticals Inc. | $206,669 | 0 |
Top Doctors Receiving Payments for Aveed
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $433,106 | 3 |
Ad
Manufacturing Companies
- Endo Pharmaceuticals Inc. $433,106
Product Information
- Type Biological
- Total Payments $433,106
- Total Doctors 0
- Transactions 3
About Aveed
Aveed is a biological associated with $433,106 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Endo Pharmaceuticals Inc..
Payment data is available from 2023 to 2023. In 2023, $433,106 was paid across 3 transactions to 0 doctors.
The most common payment nature for Aveed is "Unspecified" ($433,106, 100.0% of total).
Aveed is associated with 2 research studies, including "Multimodality Intervention to Improve Function and Metabolism in Spinal Cord Injury" ($226,437).